

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

Status: RECRUITING

Eligibility Criteria

Sex: ALL

Age: 6 years to 17 years old

Healthy Volunteers: This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Youth ages 6-17 years with ADHD as a primary diagnosis

Exclusion Criteria:

- Participants that do not have ADHD as a primary diagnosis
- Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians
- Participants that are smokers or, are pregnant

Conditions & Interventions

Interventions:

DRUG: Methylphenidate

Conditions:

ADHD, Attention Deficit Hyperactivity Disorder

Keywords:

PK Study, PD Study, Pharmacokinetics, Pharmacodynamics, Methylphenidate, MPH

More Information

Description:

The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.

Contact(s): Simon Abimosleh - simon.abimosleh@cchmc.org

Principal Investigator:

Principal Investigator ID:

Phase: PHASE4

IRB Number:

System ID: NCT03781752

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cchmc.org> to find a Study which is right for you and contact clinicalstudies@cchmc.org if you have questions or need assistance.